(UroToday.com) The KEYNOTE-052 study led to the approval of pembrolizumab for the first-line treatment of cisplatin-ineligible patients with advanced urothelial carcinoma. In this presentation, Dr. Peter O’Donnell presented updated results of 5 years of follow-up, with the median time from enrollment to data cutoff of 56.3 months.